The stock price surged 70% from its bottom and then gave back all its gains. Is the renaming effect of B&K CORP-B (02396) no match for fundamentals?

Since its listing on December 22 last year, the stock price of Huairen Biology has embarked on a "relentless decline." The company's stock price fell from an intraday high of HK$37.20 on its debut day all the way to an intraday low of HK$3.50 on July 13 this year, with a maximum decline of 90.60% during the period. After the stock price fell by 90%, Huairen Biology chose to drive a rebound through the "renaming effect." It was observed that on July 17 this year, Huairen Biology issued an announcement declaring a change of company name, and starting from 9:00 a.m. on July 22, the Chinese stock short name for trading shares on the Stock Exchange would be changed from "Huairen Biology-B" to "B&K CORP-B." After the renaming, B&K CORP-B (02396) disclosed its 26H1 financial report on August 14 and issued an announcement proposing to apply for full circulation of 21.68 million unlisted shares (approximately 18.4% of total share capital); on the same day, the company also announced a share award scheme and additionally announced details of the scheme on August 20. With a combination of positive moves, the effect was immediate. On August 17, Qingcheng New Drug's stock price closed sharply higher by 12.44%, marking the beginning of a new round of gains, after which the company's stock price went on a "five consecutive positive days," closing up 16.43% on August 21 and settling the closing price at HK$6.55, with the stock price gaining 67.95% during this rally. However, after hitting the HK$7 mark in early trading on August 24, Qingcheng New Drug's stock price did not rise further but instead fell sharply after the midday session, ultimately forming a large bearish candlestick that day, closing down 9.61%, and beginning a decline that continues to this day. During intraday trading on September 16, Qingcheng New Drug fell to a low of HK$3.5, meaning that within the nearly one-month downward range, the company's stock price had completely given back its earlier gains and returned to the lowest listing price of July 13. First Half of the Rollercoaster Ride: Why Did the Stock Price Surge Nearly 70%? To analyze Qingcheng New Drug's sharp decline from August 24 to the present, one must mention the surge from August 17 to August 21. In terms of timing, the surge that Qingcheng New Drug launched on August 17 closely followed its interim report and full circulation announcement on August 14. In fact, from the financial report data, Qingcheng New Drug's 26H1 performance could not be called "positive." Data showed that in 2026H1, the company's revenue was mainly interest income, with total revenue of only about 1 million yuan, but the corresponding net loss attributable to shareholders reached 122 million yuan, expanding by 40.65% year-on-year; at the same time, the company's cash and equivalents for the period fell from 632 million yuan to 536 million yuan, a year-on-year decrease of 15.3%. According to the financial report, the approximately HK$670 million raised in the 2025 IPO was Qingcheng New Drug's main source of funds. At a pace of approximately 61.27 million yuan in R&D investment per half-year, the company's cash reserves could only support about 8-9 months of operations. However, in the financial report, Qingcheng New Drug disclosed the latest R&D progress of its core products Pro-101-1/Pro-101-2. In the report, the company confirmed that Pro-101-1 had entered Phase IIIa (40 subjects fully enrolled) and Pro-101-2 had completed Phase II enrollment of 160 subjects, meaning the company's core products had reached a key milestone in transitioning from "early concept" to "clinical validation." In terms of product positioning, the only PDGF drug currently approved globally, Regranex, has not yet entered the domestic market, and the company's core products Pro-101-1/Pro-101-2, as among the first domestic PDGF-BB candidate drugs, have a certain first-mover advantage. Therefore, from August 17 to August 21, the internal logic behind Qingcheng New Drug's sharp stock price rally was that, after combining the company's renaming effect and the expected positive of full circulation, the market began to trade the medium- to long-term value of the company's core products' "scarcity in the PDGF track + approaching clinical milestones." From the market performance, it is not difficult to see that from August 3 to August 14, before this rally began, Qingcheng New Drug's stock price continued to move narrowly sideways in the HK$3.65-3.97 range, with average daily turnover of only 0.005%-0.03%. But starting from August 17, the company's stock price began a continuous volume-backed rally, gaining nearly 70% over 5 trading days, exhibiting a typical pulse-like for a low-float stock under news catalysis. It was observed that before August 17, Qingcheng New Drug's average daily trading volume was only 10,520 shares, but afterward its average daily trading volume reached 95,840 shares, with volume expanding about 9 times. Especially on August 21, Qingcheng New Drug's single-day turnover reached HK$1.12 million, with a turnover rate of 0.15%, which is an abnormally active level among Hong Kong innovative drug stocks not included in Stock Connect. But at this time, on the technical front, multiple indicators including RSI, KDJ, and BIAS also issued overbought correction signals. In conjunction with volume, the rapid rise in both price and volume, although confirming a short-term bullish trend for Qingcheng New Drug, saw its trading volume peak on August 21 and then show consecutive signs of volume decay on August 24 and August 25. Moreover, on August 24, after intraday gains pushed the price to HK$7.00, it fell sharply back to HK$5.20, forming an obvious long upper-shadow bearish candlestick, a typical top reversal signal. Whether It Can Stop Falling May Still Depend on Fundamental Catalysts Returning to the market, in fact, from August 24 to the present, Qingcheng New Drug has gone through 4 dynamic stages, presenting a pattern of "high-level volume declineweak sideways movementsecond bottom testaccelerated decline." As mentioned above, on August 24, Qingcheng New Drug's stock price formally formed a stage top at HK$7. After the failed intraday breakout that day, it triggered a high-level volume decline that continued until August 27, with the stock price falling 17.5% during the period; afterward, from August 28 to September 4, the company's stock price entered a weak sideways structure of "can't fall, can't buy," with turnover on multiple trading days during this period amounting to less than HK$100,000. In addition to extremely low liquidity, external buying support was also severely insufficient. During the above weak sideways period, the bearish trend in the market actually continued, and after the company's stock price fell below the previous platform near HK$4.5 on September 7, a second bottom test lasting 5 trading days occurred, which in turn triggered the release of panic selling from September 14 to September 16, causing a further volume-backed decline in the company's stock price. From the current market structure, because Qingcheng New Drug's closing price of HK$3.70 on September 16 had already fallen below the August 25 low of HK$4.90 and the September 7 low of HK$3.93, this confirmed a short-term trend breakdown. On the technical front, Qingcheng New Drug's RSI6 indicator is currently below 20, while KDJ remains at a low level and BIAS is significantly negative, with short-term oversold signals obvious. At the same time, its corresponding MACD green bars are still expanding, OBV continues to decline, and in terms of volume, there has been no reversal combination of "shrinking volume to stop the decline + volume-backed bullish candle recovering the moving averages." Generally speaking, the above market signals collectively indicate not a bottom reversal structure, but a weak downward channel after a high-level volume top. In fact, on September 4, Qingcheng New Drug had already issued its latest announcement, declaring that the shareholders' meeting had approved full circulation and the share award, meaning the earlier positive news had landed. However, judging from the subsequent market trend, the market clearly did not price it around "liquidity improvement" but instead continued to decline, indicating that the current dominant logic in the market may not be liquidity improvement, but rather a high-valuation pullback and potential dilution pressure under low performance support. In fact, this rollercoaster ride has made the trading logic of both on-market and off-market investors quite clear, namely the medium- to long-term value space of the company's core products in terms of "probability of clinical success + long-term market potential." And Qingcheng New Drug's stock price performance of surging in August this year and then falling back is essentially a rapid compression of the earlier sentiment premium. The current market attitude is actually very clear: a subsequent stock price reversal for Qingcheng New Drug still depends on clinical data, regulatory communication, or commercialization cooperation progress for its core products. Before the company has commercialization revenue, it may be difficult to support its high valuation on the full circulation positive alone.